2026-10-13T22:31:53Z https://api.figshare.com/v2/oai

oai:figshare.com:article/33871786 2026-09-17T05:30:46Z category_696 portal_316 item_type_3 month_year_09_2026

Supplementary file 1_Vancomycin-induced immune hemolytic anemia: a case report and literature review.pdf Ruochen Zhang (3434996) Yanan Wang (123548) Zhongying Wang (1702927) Yu Tao (305214) Sujuan Zheng (639187) Shenghao Xu (1711933) Ling Wang (56577) Dong Xiang (1900951) Jiang Wu (174815) Genetic Immunology diagnosis and treatment of hemolysis drug antibody titers drug-induced immune hemolytic anemia (DIIHA) serological test vancomycin <p>Drug-induced immune hemolytic anemia (DIIHA) is a rare but potentially life-threatening adverse drug reaction. Although more than 150 drugs have been reported to induce DIIHA, vancomycin, a glycopeptide antibiotic widely used in clinical practice, is rarely associated with hemolysis, making it prone to underdiagnosis or misdiagnosis. This article reports a case of vancomycin-induced DIIHA in a 64-year-old female patient after right revision knee arthroplasty (RKA). This study investigated the serological tests associated with vancomycin and tracks drug antibody titers through longitudinal monitoring during clinical diagnosis and treatment. Additionally, a literature review identified and summarized five previously reported cases of vancomycin-induced immune hemolytic anemia. Clinicians should maintain a high index of suspicion for hemolysis associated with vancomycin, including its use in bone cement. Early recognition, prompt withdrawal of the offending agent, and transfusion support are imperative for improving patient outcomes with DIIHA.</p> 2026-09-17T05:30:46Z Dataset Dataset 10.3389/fimmu.2026.1842837.s001 https://figshare.com/articles/dataset/Supplementary_file_1_Vancomycin-induced_immune_hemolytic_anemia_a_case_report_and_literature_review_pdf/33871786 CC BY 4.0